Understanding the burden of weekly somatrogon injections compared with daily somatropin injections in children with growth hormone deficiency: a plain language summary of publication Authors: Aristides K Maniatis, Mauri Carakushansky, Sonya Galcheva, Gnanagurudasan Prakasam, Larry A Fox, Adriana Dankovcikova, Jane Loftus, Andrew A Palladino, Maria de los Angeles Resa, Carrie Turich Taylor, Mehul T Dattani, Jan Lebl Published: 2024 ABSTRACT Abstract• For children with growth hormone deficiency, once-weekly somatrogon injections were less of a burden than once-daily somatropin injections.• The safety of weekly somatrogon was similar to that of daily somatropin.• Compared with daily somatropin injections, children with growth hormone deficiency may be less likely to miss weekly somatrogon injections. ○ This is because weekly somatrogon injections were less of a burden and were less likely to interfere with daily activities compared with daily somatropin injections.The purpose of this plain language summary is to help you to understand the findings from recent research.• Somatrogon is used to treat the condition under study that is discussed in this summary. Approval varies by country; please check with your local provider for more details.• The results of this study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence and not on the results of a single study.This original scientific article on which this summary is based was published in the Journal of the Endocrine Society and can be accessed for free at: https://academic.oup.com/jes/article/6/10/bvac117/6695276. The details of the original article are as follows: Aristides K. Maniatis, Mauri Carakushansky, Sonya Galcheva, Gnanagurudasan Prakasam, Larry A. Fox, Adriana Dankovcikova, Jane Loftus, Andrew A. Palladino, Maria de los Angeles Resa, Carrie Turich Taylor, Mehul T. Dattani, Jan Lebl. Treatment burden of weekly somatrogon versus daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc 2022; 6(10): bvac117. DOI: 10.1210/jendso/bvac117.Keywords: growth hormone, growth hormone deficiency, somatrogon, somatropin Click here to view the PDF Acknowledgments Writing support for this summary was provided by Chu Kong Liew, PhD, CMPP, at Envision Pharma Group, and was funded by Pfizer. All authors of the full article were involved in preparing this summary and approved the content in the final version. Pfizer would like to thank all of the people who took part in this study. Declarations Ethics approval and consent to participate: As described in the original publication, the study was conducted in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice and the Declaration of Helsinki and was registered on ClinicalTrials.gov (NCT03831880). The study protocol was approved by the institutional review board and/or independent ethics committee of the participating study centers. Parents or guardians of each patient provided signed, informed, written consent before any study procedures were started. Consent for publication: Not applicable. Author contributions: Aristides K. Maniatis: Conceptualization; Investigation; Project administration; Resources; Supervision; Visualization; Writing – original draft; Writing – review & editing. Mauri Carakushansky: Investigation; Writing – original draft; Writing – review & editing. Sonya Galcheva: Investigation; Writing – original draft; Writing – review & editing. Gnanagurudasan Prakasam: Investigation; Supervision; Writing – original draft; Writing – review & editing. Larry A. Fox: Investigation; Writing – original draft; Writing – review & editing. Adriana Dankovcikova: Investigation; Writing – original draft; Writing – review & editing. Jane Loftus: Conceptualization; Resources; Validation; Writing – original draft; Writing – review & editing. Andrew A. Palladino: Conceptualization; Data curation; Investigation; Supervision; Writing – original draft; Writing – review & editing. Maria de los Angeles Resa: Formal analysis; Writing – original draft; Writing – review & editing. Carrie Turich Taylor: Data curation; Investigation; Supervision; Writing – original draft; Writing – review & editing. Mehul T. Dattani: Investigation; Writing – original draft; Writing – review & editing. Jan Lebl: Investigation; Writing – original draft; Writing – review & editing. Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Pfizer. Competing interests: A.K.M. has participated in advisory boards and served on a speakers bureau for Ascendis Pharma, Novo Nordisk, OPKO, and Pfizer, and has received research funding from Ascendis Pharma, Novo Nordisk, OPKO, and Pfizer. A.D. has received research funding from Pfizer and served on a speakers bureau for Pfizer, Novo Nordisk, and Merck. M.T.D. has participated in advisory boards for Novo Nordisk, is a consultant for Pfizer and Ipsen, and has served on a speakers bureau for Pfizer, Novo Nordisk, Sandoz, and Ipsen. J.L. has received research funding from Pfizer and Rare Thyroid Therapeutics, and served on a speakers bureau for Pfizer, Novo Nordisk, Merck, and Sandoz. J.L., A.A.P., M.A.R., and C.T.T. are employees and stockholders of Pfizer. M.C., S.G., G.P., and L.A.F. have no conflicts of interest to declare. Availability of data and materials: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.